Kornimate/medical-research-clean huggingface dataset:
a web-based approach to treating cardiovascular disease risk in employees with metabolic syndrome

Conditions: Metabolic Syndrome; Cardiovascular Disease; Atherosclerosis; Obesity

Summary: the purpose of behhs is first to assess the baseline sub-clinical disease in a population of baptist health employees who have metabolic syndrome, a known contributor to cardiovascular disease. second, the investigators wish to encourage a healthy lifestyle through personalized nutrition and fitness advice, delivered as part of a web based program, which will in turn lead to increases in heart healthy behaviors such as increased consumption of heart healthy foods, increased exercise initiation, and more positive attitudes about health. to assess this, the investigators plan to randomize 200 employees with metabolic syndrome to either the new web-based diet and lifestyle program, or to care-as-usual, which is the currently offered mywellnessadvantage and webmd websites. the investigators hypothesize that the web-based group will show greater improvements in physical health (such as weight loss, cholesterol reduction, etc.) as well as increased consumption of heart healthy foods, exercise initiation, and quality of sleep as measured by surveys administered at the 4,8, and 12 month follow-up appointments.


Eligibility criteria:
inclusion criteria: * employee of baptist health * access to internet * has a smart phone (android or apple supported) with data plan * has an email address * diagnosis of three or more of the following: 1. waist circumference \>=40 inches in and male and \>= 35 inches in a female 2. fasting triglyceride level \> 150 mg/dl\* 3. hdl-c \< 40 mg/dl in men or \< 50 mg/dl in women\* 4. bp \> 130/85 mm hg\* 5. fasting blood glucose \> 110 mg/dl * or currently on medication to treat the abnormal condition exclusion criteria: 1. prior history of major cardiovascular events (angina, myocardial infarction, prior coronary revascularization 2. any woman of childbearing potential who is pregnant, breastfeeding/currently lactating, seeking to become pregnant or suspects that she may be pregnant\*\* 3. active treatment for cancer 4. known history of a bilateral mastectomy 5. known history of diabetes (already being treated as high-risk group, would not qualify as having metabolic syndrome for purposes of our study) 6. known history of chronic obstructive pulmonary disease 7. currently in atrial fibrillation 8. known history of hypo-tension 9. known history of heart failure 10. known history of aortic valve stenosis 11. known history of heart block 12. chest ct scan in the last year 13. cognitive inability as judged by the interviewer

Keywords: employees metabolic syndrome obesity sub-clinical cardiovascular disease weight loss diet
adipose derived mesenchymal stem cell characteristics in anal fistulas

Conditions: Perianal Fistula; Adipose Tissue; Tissue Transplantation

Summary: this study investigated the cellular and molecular characteristics of at-mscs obtained from autologous at therapy in patients with high transphincteric perianal fistulas of crytoglandular origin. adipose tissue was injected into anal fistulas. characteristics of adipose tissue mesenchymal stemcells (at-msc) was investigated and compared in patients with fistula that healed after the treatment (responders) to patients who failed to heal (non-responders)

injection with allogene or autologous stem cells has been reported to be efficient treatment of perianal fistulas. an alternative to this treatment could be injection with freshly collected autologous adipose tissue. in this study 27 patients with cryptoglandular anal fistulas were treated with freshly collected autologous adipose tissue.a clinical assessment of the patient prior to inclusion was undertaken and a loose seton placed for at least 6 weeks prior to fat injection. an mri of the pelvis was performed before inclusion. fistulas with secondary tracts and/or cavities were excluded. the operation was performed in one procedure including liposuction and injection of adipose tissue. a sample of adipose tissue from all 27 patients was analyzed. at-mscs were isolated and characterized using cellular and molecular analyses. clinical and mri-scanning evaluation of fistula healing and evaluation of ano-rectal function was performed after 6 months. at-mscs phenotype was compared between responders and non-responders with respect to fistula healing. the evaluation of the at-mscs was performed in a blinded manner.

Eligibility criteria:
inclusion criteria: * high trans-sphincteric fistulas * fistula confirmed and classified by an mri. * seton (\> 6 weeks) prior to fat injection * informed, written consent. exclusion criteria: anovaginal fistula * active sepsis * ibd, immunodeficiency, prior pelvic irradiation and malignancy * insulin dependent diabetes * more than 4 prior attempts of fistula closure * tobacco smoking or nicotine substitution 8 weeks prior to fat injection. * pregnancy * psychiatric disorders * bmi ≥ 35 or bmi\<20 * active tuberculosis * patient less than 18 years * unable to undergo mri

Keywords: autologous adipose tissue, mesenchymal stem cells, perianal fistula
hamstring viscoelasticity and low back pain

Conditions: Low Back Pain; Athletic Injuries

Summary: low back pain (lbp) is a prevalent issue among adolescent rowers, particularly males aged 14 to 16 years, with a high lifetime prevalence (94%) and point prevalence (65%). one of the mechanisms of lower back pain in rowing athletes is about the elasticity, stiffness and tone of the hamstring muscle. current literature shows that stretching exercises, strengthening exercises and kinesiotaping affects hamstring viscoelasticity in various ways. stretching exercises affect hamstring muscle tone and elasticity, strengthening exercises affect muscle stiffness and kinesiotaping affects muscle tone. while the effects of each of these interventions on viscoelastic properties individually are examined in the literature, studies comparing the effects of changes in viscoelastic properties caused by these interventions on low back pain, athletic disability index and athletic performance in rowers and their superiority among each other are lacking. the goal of this study is to change the viscoelasticity of the hamstring muscles and examine its effect on low back pain, disability index and athletic performance.

volunteer male elite rowing athletes between the ages of 14 and 18 who score 3/10 or higher on the numeric pain rating scale at the time of activity will be included in the study. signed voluntary consent will be obtained from participants and their legal representatives. participants will be divided into three groups. study groups will be as follows: a) ballistic hamstring stretching exercise b) hamstring extender exercise c) kinesiotaping

Eligibility criteria:
inclusion criteria: * being between ages 14 and 18 and male gender * having been rowing at an elite level for at least one year with a professional team * having pain 3/10 or higher on nprs * participating to the study in a voluntary basis. exclusion criteria: * having limitation in lower extremity range of motion that limits completion of interventions * having a musculoskeletal injury involving the lower extremity in the last 6 months. * having undergone a operation in the last 6 months. * failing to complete any of interventions. * wanting to quit from study.

Keywords: ballistic stretching athletic tape eccentric exercise low back pain athletic performance
mercury ii - compare the efficacy and safety of lipid lowering agents atorvastatin and simvastatin with rosuvastatin in high risk subjects with type iia and iib hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: the purpose of this study is to determine whether treatment with rosuvastatin following atorvastatin or simvastatin treatment will improve health outcomes for patients at high risk of coronary heart disease compared to atorvastatin and simvastatin alone.


Eligibility criteria:
inclusion criteria: * discontinuation of all cholesterol lowing drugs, including dietary supplements. * documented history of, or high risk of coronary heart disease or other established atherosclerotic disease. exclusion criteria: * the use of lipid lowering drugs or dietary supplements after visit 1. * active arterial disease eg unstable angina, or recent arterial surgery * uncontrolled hypertension, hypothyroidism, alcohol or drug abuse. * abnormal laboratory parameters as defined in the protocol.

Keywords: cholesterol hypercholesterolemia coronary heart disease low density lipoproteins rosuvastatin atorvastatin simvastatin
vaginal estriol in multiple sclerosis

Conditions: Multiple Sclerosis; Neurogenic Bladder

Summary: study to evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with rrms. the secondary objective is to evaluate the potential role of vaginal estriol in re-myelination in rrms patients.

pilot project to determine the effectiveness of 1 mg transvaginal estriol, as an adjunctive therapy for female ms patients. the goal is to recruit 20 patients from the ms clinic in the neurology department of texas tech university health sciences center. this study has been planned in collaboration with reproductive endocrinology, endocrinology, gynecology and basic science. the 1mg transvaginal dose was chosen after careful search of the literature and consultation with collaborators. single-group pilot study. subjects: patients with relapsing remitting ms and urogenital symptoms (frequency, urgency, frequent urinary tract infections, incontinence) will be invited to participate in the study. enrollment will be during their scheduled clinic appointment. some candidates (patients of the primary investigator) may be contacted by phone and invited to participate in the study. the clinical trial will be explained to potential participants in detail, reviewing the objectives and methodology of the study. there will be adequate time allotted to answer any questions or concerns from the potential participants. those patients interested in participating in the study will be asked to sign the consent form. in order to remind patients about their follow-up visits, lab work, etc., they will be contacted routinely. participants will be instructed to call in case of questions or concerns. patients will be evaluated clinically during their scheduled follow up in which a full neurological exam will be performed during each visit. patients will be instructed by the primary investigator how to correctly use the vaginal cream. this will be done at their enrolment and reinforced by the principal investigator, during their follow up visits.

Eligibility criteria:
inclusion criteria: 1. female patients with rrms over the age of 40 to 65. * being prescribed vaginal estriol to treat their urogenital symptoms such as frequency, urgency, incontinence and frequent urinary tract infections. * patients that had underwent chemical or surgical hysterectomy. 2. patients will continue their current disease modifying agent for ms during the trial. exclusion criteria: 1. patients with history of breast cancer, uterine or ovarian cancer. 2. patients with progressive multiple sclerosis 3. patients who are unable to undergo an mri 4. males 5. patient is already on vaginal or oral or transdermal estrogens 6. pregnant or breast-feeding patients 7. patient taking sex hormones eg testosterone for libido 8. patients taking dhea or otc related products that could influence the hormonal milieu. 9. patient with prolapse uterus or conditions that would impact on transvaginal absorption of estriol

Keywords: remyelination urogenital health multiple sclerosis
motivational interviewing for stroke

Conditions: Acute Stroke; Transient Ischemic Attack

Summary: motivational interviewing (mi) is a style of communication designed to elicit a person's own reasons for change to drive commitment toward a goal. the goal of this study is to assess the effect of trainee-led mi on patients diagnosed with acute stroke or tia attributable to modifiable risk factors in comparison to conventional post-stroke counseling, based on patient outcomes, and meaning of work and sense of fulfillment for trainees.


Eligibility criteria:
inclusion criteria: * patient presentation consistent with a stroke or tia * patient is a current tobacco user and tobacco use contributed to the stroke * resident enrolled in study assigned to vascular neurology service during patient admission. exclusion criteria: * patient unable or unwilling to follow up in the outpatient stroke clinic after discharge * patient has cognitive impairment or aphasia that would preclude meaningful participation in motivational interview (defined as a score of 0 on the national institute of health stroke scale \[nihss\] questions 1 and 9)
researching the effectiveness of a alivis, a digital health application for borderline personality disorder

Conditions: Borderline Personality Disorder (BPD)

Summary: this randomized controlled trial (rct) with 470 patients diagnosed with borderline personality disorder (bpd) aims to investigate the effectiveness of the unguided digital therapeutic alivis for patients with bpd as defined in dsm-5. inclusion criteria are: male, female or non-binary, age 18-65 years, diagnosis of bpd (confirmed by scid-5-pd), borderline severity score (cut-off) of ≥ 1.07 on the borderline symptoms list 23 (bsl-23), stable treatment (psychotherapy, medication, no treatment, ...) for at least 30 days at the time of inclusion, consent to emergency plan for suicidal crises, consent to participation, and sufficient german language skills. exclusion criteria are: plans to change in treatment (psychotherapy, medication, ...) in the upcoming 6 months after inclusion, comorbid diagnosis of substance use disorder or lifetime diagnosis of psychotic disorder, physical condition that can cause severe psychiatric symptoms, acute decompensation of mental health, bmi \&lt;15, and prior use of the digital intervention priovi. patients will be randomized and allocated to either an intervention group, in which they will receive access to alivis in addition to treatment as usual (tau; n=235), or to a control group, in which they will receive access to tau (n=235). the primary endpoint will be bpd symptoms with three months post-allocation (t1) being the primary timepoint for assessment of effectiveness. six (t2) and twelve (t3) months post-allocation will be used as follow-up assessment of endpoints. secondary endpoints will be depressive symptoms, anxiety symptoms, costs caused due to the patient's bpd, social functioning, health-related quality of life, and patient activation.


Eligibility criteria:
inclusion criteria: * diagnosis of bpd * borderline severity score (cut-off) of ≥ 1.07 on the bsl-23 * stable treatment (e.g., psychotherapy, medication, no treatment) for at least 30 days at the time of inclusion * consent to emergency plan for suicidal crises * consent to participation * sufficient knowledge of the german language exclusion criteria: * plans to change treatment (e.g., psychotherapy, medication) in the upcoming 6 months after inclusion * comorbid diagnosis of substance use disorder * lifetime diagnosis of psychotic disorder like schizophrenia or schizoaffective disorder (except non-transitory paranoid ideas that can be concomitant with bpd and in which the ability to test reality is mostly preserved) * diagnosis of a physical condition that can cause serious psychiatric symptoms * acute decompensation of mental health symptoms, e.g. acute manic state or acute suicidality * bmi \&lt; 15 * current psychiatric day-care or inpatient treatment * prior use of the digital intervention priovi

Keywords: digital intervention borderline personality disorder rct dialectical behavior therapy
postoperative epidural analgesia in spine fusion surgery

Conditions: Pain

Summary: we aim to compare the analgesic effect of 0.125% bupivacaine hcl, 0.125% bupivacaine hcl + morphine sulphate 3 mg, 0.125% bupivacaine hcl + fentanyl 100 micro gram both at rest and mobilization maneuvers.


Eligibility criteria:
inclusion criteria: * patients undergoing spine fusion surgery. exclusion criteria: * drug addiction. intraoperative dural tear. uses of opioids drug for any reason in the previous 48 hours. mental dysfunction. spinal fusion for any infectious or malignant causes.

Keywords: postoperative spine surgery
patisiran in patients with hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) disease progression post-liver transplant

Conditions: Amyloidosis, Familial; Transthyretin Amyloidosis

Summary: the purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of patisiran in participants with hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) with disease progression after liver transplant.


Eligibility criteria:
inclusion criteria: * received liver transplant for treatment of hattr amyloidosis ≥12 months before study start * has increase in polyneuropathy disability (pnd) score after liver transplant * has received stable immunosuppressive regimen with ≤10 mg/day of prednisone for at least 3 months before study start * has karnofsky performance status (kps) of ≥70% * has vitamin a level greater than or equal to lower limit of normal exclusion criteria: * has previously received inotersen or patisiran * has clinically significant liver function test abnormalities * has known portal hypertension with ascites * has estimated glomerular filtration rate (egfr) ≤30 ml/min/1.73 m\^2 * has known leptomeningeal amyloidosis * has infection with hepatitis b, hepatitis c or human immunodeficiency virus (hiv) * has new york heart association heart failure classification of \>2 * is wheelchair bound or bedridden * has received organ transplants other than liver transplant * will be using another tetramer stabilizer during the study
the use of impella rp support system in patients with right heart failure

Conditions: Right Heart Failure

Summary: the use of impella rp is safe, feasible and provides a hemodynamic benefit in patients with right ventricular failure.


Eligibility criteria:
inclusion criteria: 1. patients that have developed signs of right ventricular failure either: a) within 48 hours post-implantation of an fda approved implantable surgical lvad (left ventricular assist device )(cohort a) or b) subsequent to postcardiotomy shock within 48 hours post surgery or post myocardial infarction (cohort b). 2. age ≥18 years old 3. signed informed consent exclusion criteria 1. intermacs 1 patients (critical cardiogenic shock patient who is "crashing and burning", has life-threatening hypotension and rapidly escalating inotropic or pressor support, with critical organ hypoperfusion often confirmed by worsening acidosis and lactate levels) 2. evidence of acute neurologic injury 3. ra(right atrium),rv (right ventricle) and/or pa (pulmonary artery) thrombus 4. intolerance to anticoagulant or antiplatelet therapies 5. existing congenital heart disease that would preclude the insertion of the device. 6. participation in any other clinical investigation that is likely to confound study results or affect study outcome 7. acute myocardial infarction (ami) with mechanical complications ( ventricular septal defect, myocardial rupture, papillary muscle rupture)
evaluation of a walking school bus program

Conditions: Obesity; Physical Activity

Summary: just two generations ago, walking or bicycling to school was the norm for a substantial number of us children, e.g. 48% of children walked or biked to school in 1969 versus only 13% in 2009. this decline occurred in the same timeframe as the childhood obesity epidemic, which is at record high levels in the us and affects low-income and ethnic minority children the most. this project will test "the walking school bus" (wsb) program, in which children walk to and from school with adults, and its impact on low-income, ethnic minority children's walking to school, physical activity, and risk for obesity. ultimately, this line of research has the potential to provide a low-cost, easy to disseminate program to reduce risk of obesity and cancer for at-risk children. the investigators specific aims among 3rd-5th grade children include: sa1) to recruit 770 child-parent dyads from 22 elementary schools over 4 years and conduct a cluster randomized controlled trial to assess the efficacy of a wsb program on children's walking to school, physical activity, and bmi z-score over a school-year sa2) to collect and analyze data on individual-, school-, and macro-level influences on changes to children's walking to school resulting from the wsb program the primary hypotheses to be tested, in comparison to control children, include: h1) the wsb program will increase children's walking to school over a school-year. h1a) parents' outcome expectations and self-efficacy will mediate the relationship between the wsb and changes to children's walking to school. h1b) walkability, safety, and acculturation will moderate changes to children's walking to school. h2) the wsb program will increase children's physical activity and decrease bmi z-scores over a school-year. h3) the wsb program will increase school-level pedestrian safety behaviors over a school-year.


Eligibility criteria:
inclusion criteria: * physically capable of walking to and from school * live within 1-mile of school or parents agree to regularly drop off children within 1-mile of school * attend a study school and enrolled in 3rd, 4th, or 5th grade exclusion criteria: * another child from the same household is enrolled in the study

Keywords: safe routes to school walking school bus cluster randomized controlled trial physical activity obesity overweight
effects of diathermy application on immediate sports performance of paralympic swimmers

Conditions: Athletic Performance

Summary: this study aims to evaluate the potential benefits of monopolar capacitive resistive radio-frequency (448 khz) on the sports performance of paralympic swimmers.

a randomized, double-blind, crossover, controlled and sham-controlled clinical trial evaluate the effectiveness of resistive capacitive diathermy as sports performance enhancement of paralympic elite swimmers compared with a "sham" diathermy treatment and with a control group. the resistive capacitive diathermy is a medical device supplying low (448 khz) radiofrequency with a maximum output power of 200 w, used to improve physiological aspects and theoretically allowing improvement in swimming performance. the sham diathermy treatment is administered with the device set on "on" but not active (not supplying energy) and control group will not receive anything, randomly assigned to either resistive capacitive diathermy treatment (group 1), sham-treatment (group 2) or control (group 3) athletes are submitted to a twenty minutes session prior swimming performance. the main outcome measures are the simulate swimming time trial (seconds) to assess time completing the presented course and borg scale for perceived exertion. outcome measures are administered at completing each time trial.

Eligibility criteria:
inclusion criteria: * informed consent signed. * age between 18 y 70 years old. * already in the position of the international paralympic committee (ipc) classification. * know their personal mark (50-100mts). * having the capacity to fill and understand questionnaires, understand and follow verbal orders. exclusion criteria: * pregnancy. * use of pacemakers or other types of electronic implants * non-intact skin (open wounds or recent burns) * thrombophlebitis * known allergy to nickel and chromium * symptomatic anemia (hemoglobin below 12g / dl presenting any of these symptoms: tiredness, shortness of breath, dizziness, palpitations or headache). * present feverish process elimination criteria: * revocation of inform consent. * attend to less than three visits.